KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash & Equivalents (2016 - 2025)

Jazz Pharmaceuticals has reported Cash & Equivalents over the past 16 years, most recently at $1.4 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 42.31% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, down 42.31%, while the annual FY2025 figure was $1.4 billion, 42.31% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $1.4 billion at Jazz Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $2.4 billion in Q4 2024 and troughed at $490.8 million in Q1 2022.
  • A 5-year average of $1.3 billion and a median of $1.3 billion in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 198.96% in 2021 and later tumbled 76.6% in 2022.
  • Year by year, Cash & Equivalents stood at $591.4 million in 2021, then soared by 49.04% to $881.5 million in 2022, then skyrocketed by 70.88% to $1.5 billion in 2023, then soared by 60.18% to $2.4 billion in 2024, then tumbled by 42.31% to $1.4 billion in 2025.
  • Business Quant data shows Cash & Equivalents for JAZZ at $1.4 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.